S Rodríguez-Segade1, J Rodríguez2, F Camiña3. 1. Department of Biochemistry and Molecular Biology, University of Santiago de Compostela. Santiago de Compostela, Spain; Clinical Biochemistry Laboratory, University Hospital Complex of Santiago de Compostela. Santiago de Compostela, Spain. 2. Clinical Biochemistry Laboratory, University Hospital Complex of Santiago de Compostela. Santiago de Compostela, Spain. 3. Department of Biochemistry and Molecular Biology, University of Santiago de Compostela. Santiago de Compostela, Spain. Electronic address: felix.camina@usc.es.
Abstract
AIMS: There is increasing interest in using fructosamine measurements in screening for or managing diabetes, yet uncertainty remains as to whether these measurements should be corrected for variation in serum protein concentrations. METHODS: We considered all sets of simultaneous measurements of fructosamine, albumin, total serum protein (TP), fasting plasma glucose (FPG) and HbA1C recorded in our laboratory over 10years. The relationships between fructosamine and other variables were studied by multivariate linear regression and other analyses, and receiver operating curves (ROCs) were analysed to compare the diabetes screening performance of uncorrected fructosamine to those of albumin-corrected fructosamine (FAAlb) and TP-corrected fructosamine (FATP). RESULTS: 40,938 sets of measurements were collected from 20,114 patients. Though correlation between fructosamine and serum proteins was strongest among patients with HbA1C <6.5% (48mmol/mol), it was also significant in the whole sample (r=0.193 for albumin, r=0.213 for TP). With diabetes defined by HbA1C ≥6.5% (48mmol/mol), the areas under the ROCs of FAAlb (0.905) and FATP (0.895) were both significantly greater (P<0.001) than that of uncorrected fructosamine (0.878). Correction of fructosamine for albumin or TP slightly improved its correlation with HbA1C. There was no correlation of protein (albumin or TP) with log(fructosamine/protein). CONCLUSIONS: Fructosamine concentration correlates significantly with albumin and total protein concentrations throughout their ranges. Correction of fructosamine improves its correlation with HbA1C and its performance in detecting diabetes.
AIMS: There is increasing interest in using fructosamine measurements in screening for or managing diabetes, yet uncertainty remains as to whether these measurements should be corrected for variation in serum protein concentrations. METHODS: We considered all sets of simultaneous measurements of fructosamine, albumin, total serum protein (TP), fasting plasma glucose (FPG) and HbA1C recorded in our laboratory over 10years. The relationships between fructosamine and other variables were studied by multivariate linear regression and other analyses, and receiver operating curves (ROCs) were analysed to compare the diabetes screening performance of uncorrected fructosamine to those of albumin-corrected fructosamine (FAAlb) and TP-corrected fructosamine (FATP). RESULTS: 40,938 sets of measurements were collected from 20,114 patients. Though correlation between fructosamine and serum proteins was strongest among patients with HbA1C <6.5% (48mmol/mol), it was also significant in the whole sample (r=0.193 for albumin, r=0.213 for TP). With diabetes defined by HbA1C ≥6.5% (48mmol/mol), the areas under the ROCs of FAAlb (0.905) and FATP (0.895) were both significantly greater (P<0.001) than that of uncorrected fructosamine (0.878). Correction of fructosamine for albumin or TP slightly improved its correlation with HbA1C. There was no correlation of protein (albumin or TP) with log(fructosamine/protein). CONCLUSIONS:Fructosamine concentration correlates significantly with albumin and total protein concentrations throughout their ranges. Correction of fructosamine improves its correlation with HbA1C and its performance in detecting diabetes.
Authors: William Pedrosa; Maria de Fátima Haueisen Sander Diniz; Sandhi Maria Barreto; Pedro Guatimosim Vidigal Journal: Pract Lab Med Date: 2018-12-05
Authors: Ayo P Doumatey; Hermon Feron; Kenneth Ekoru; Jie Zhou; Adebowale Adeyemo; Charles N Rotimi Journal: Diabetes Res Clin Pract Date: 2021-06-11 Impact factor: 8.180